May 25, 2021
In a session from the PDS 2021 Virtual Super-Conference, experts discussed how POC testing capabilities enhance patient services and address antimicrobial resistance.
May 11, 2021
Melphalan flufenamide (Pepaxto; Oncopeptides AB) in combination with dexamethasone was granted accelerated approval on February 26, 2021, by the FDA for adult patients with relapsed or refractory multiple myeloma.
April 22, 2021
This indication is approved under accelerated approval based on tumor response rate and durability of response.
April 16, 2021
Nextstellis (drospirenone; estetrol) now is approved as a combined oral contraceptive for birth control.
March 22, 2021
AstraZeneca is preparing to submit its COVID-19 vaccine data to the FDA for emergency use authorization in the coming weeks.
February 27, 2021
The FDA has granted emergency use authorization status for the first single-dose vaccine for COVID-19 in the United States.
February 16, 2021
Novartis’ sacubitril/valsartan (Entresto) is now indicated for use in the treatment of chronic heart failure.
February 12, 2021
Belantamab mafodotin-blmf is now indicated for adult patients with relapsed or refractory myeloma who have received at least 4 prior therapies.
January 22, 2021
Officials with the FDA have approved cabotegravir and rilpivirine, injectable formulation (Cabenuva; ViiV Healthcare) as a complete regimen for the treatment of HIV-1 infection in adults.
January 14, 2021
On October 22, 2020, the FDA approved remdesivir (Veklury; Gilead) as the first treatment for coronavirus disease 2019 (COVID-19).
